Details of the Drug

General Information of Drug (ID: DMGSRN1)

Drug Name

Mipomersen

Synonyms

Mipomersen

Indication

Disease Entry	ICD 11	Status	REF
Familial hypercholesterolemia	5C80.00	Approved	[1], [2], [3]

Therapeutic Class

Antisense

Drug Type

Antisense drug

Sequence

GCCUCAGTCGTCTTCGCACC

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 5

Molecular Weight (mw)

7158

Topological Polar Surface Area (xlogp)

-38.1

Rotatable Bond Count (rotbonds)

156

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

157

ADMET Property

Clearance: The drug present in the plasma can be removed from the body at the rate of 0.67 mL/min/kg [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 1 - 2 month [4]
Metabolism: The drug is metabolized via the endonucleases [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.05% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.1 L/kg [4]

Chemical Identifiers

Formula: C230H305N67O122P19S19-19
IUPAC Name: [(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-3-[[(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-3-[[(2S,3S,4R,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2S,3S,4R,5S)-3-[[(2S,3S,4R,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2S,3S,4S,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-[(2R,3R,4S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]sulfanylphosphinate
Canonical SMILES: CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)([O-])S[C@H]3C[C@@H](O[C@@H]3COP(=O)([O-])S[C@H]4C[C@@H](O[C@@H]4COP(=O)([O-])S[C@H]5C[C@@H](O[C@@H]5COP(=O)([O-])S[C@H]6C[C@@H](O[C@@H]6COP(=O)([O-])S[C@H]7C[C@@H](O[C@@H]7COP(=O)([O-])S[C@H]8C[C@@H](O[C@@H]8COP(=O)([O-])S[C@H]9C[C@@H](O[C@@H]9COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)CO)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)SP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)SP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)SP(=O)([O-])OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)O
InChI: InChI=1S/C230H324N67O122P19S19/c1-97-55-278(217(309)256-177(97)231)141-45-131(112(400-141)70-381-422(327,328)442-136-50-146(283-66-108(12)196(302)275-228(283)320)406-118(136)76-387-427(337,338)448-140-54-150(294-93-253-154-191(294)266-214(243)270-200(154)306)409-120(140)78-389-428(339,340)446-138-52-148(292-91-250-151-186(240)246-89-248-188(151)292)407-121(138)79-390-430(343,344)450-169-124(413-204(160(169)373-37-27-363-17)286-59-101(5)181(235)260-221(286)313)83-394-435(353,354)455-174-128(417-209(165(174)378-42-32-368-22)291-68-110(14)198(304)277-230(291)322)87-396-434(351,352)453-172-126(415-207(163(172)376-40-30-366-20)289-62-104(8)184(238)263-224(289)316)85-395-433(349,350)452-171-123(412-206(162(171)375-39-29-365-19)288-61-103(7)183(237)262-223(288)315)82-393-432(347,348)449-168-111(69-298)410-211(159(168)372-36-26-362-16)296-95-254-155-192(296)267-215(244)271-201(155)307)439-420(323,324)384-74-117-137(51-147(405-117)284-67-109(13)197(303)276-229(284)321)444-425(333,334)388-77-119-139(53-149(408-119)293-92-252-153-190(293)265-213(242)269-199(153)305)447-426(335,336)386-71-113-132(46-142(401-113)279-56-98(2)178(232)257-218(279)310)440-421(325,326)383-73-115-135(49-145(403-115)282-65-107(11)195(301)274-227(282)319)443-424(331,332)385-75-116-134(48-144(404-116)281-64-106(10)194(300)273-226(281)318)441-423(329,330)382-72-114-133(47-143(402-114)280-57-99(3)179(233)258-219(280)311)445-429(341,342)392-81-129-176(167(380-44-34-370-24)212(419-129)297-96-255-156-193(297)268-216(245)272-202(156)308)457-438(359,360)398-86-127-173(164(377-41-31-367-21)208(416-127)290-63-105(9)185(239)264-225(290)317)454-436(355,356)399-88-130-175(166(379-43-33-369-23)210(418-130)295-94-251-152-187(241)247-90-249-189(152)295)456-437(357,358)397-84-125-170(161(374-38-28-364-18)205(414-125)287-60-102(6)182(236)261-222(287)314)451-431(345,346)391-80-122-157(299)158(371-35-25-361-15)203(411-122)285-58-100(4)180(234)259-220(285)312/h55-68,89-96,111-150,157-176,203-212,298-299H,25-54,69-88H2,1-24H3,(H,323,324)(H,325,326)(H,327,328)(H,329,330)(H,331,332)(H,333,334)(H,335,336)(H,337,338)(H,339,340)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,351,352)(H,353,354)(H,355,356)(H,357,358)(H,359,360)(H2,231,256,309)(H2,232,257,310)(H2,233,258,311)(H2,234,259,312)(H2,235,260,313)(H2,236,261,314)(H2,237,262,315)(H2,238,263,316)(H2,239,264,317)(H2,240,246,248)(H2,241,247,249)(H,273,300,318)(H,274,301,319)(H,275,302,320)(H,276,303,321)(H,277,304,322)(H3,242,265,269,305)(H3,243,266,270,306)(H3,244,267,271,307)(H3,245,268,272,308)/p-19/t111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122+,123-,124-,125+,126-,127+,128-,129-,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,157+,158+,159-,160-,161+,162-,163-,164+,165-,166+,167-,168-,169-,170+,171-,172-,173+,174-,175+,176-,203+,204-,205+,206-,207-,208+,209-,210+,211-,212-/m1/s1
InChIKey: TZRFSLHOCZEXCC-HIVFKXHNSA-A

Cross-matching ID

PubChem CID: 71301230
CAS Number: 1000120-98-8
DrugBank ID: DB05528
TTD ID: D08CVQ

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
APOB messenger RNA (APOB mRNA)	TTN1IE2	APOB_HUMAN	Not Available	[6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification

05 Endocrine, nutritional or metabolic disease

Disease Class

ICD-11: 5A11 Type 2 diabetes mellitus

The Studied Tissue

Whole blood

The Studied Disease

Familial hypercholesterolemia [ICD-11:5A11]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
APOB messenger RNA (APOB mRNA)	DTT	APOB	9.53E-01	0.03	0.18

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Mipomersen

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[9]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[10]
-----------

Coadministration of a Drug Treating the Disease Different from Mipomersen (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Mipomersen and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[11]
Tagraxofusp	DM9HQ5U	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Tagraxofusp.	Acute myeloid leukaemia [2A60]	[12]
Gilteritinib	DMWQ4MZ	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Gilteritinib.	Acute myeloid leukaemia [2A60]	[12]
Inotersen	DMJ93CT	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Inotersen.	Amyloidosis [5D00]	[12]
Bedaquiline	DM3906J	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[12]
Oxymetholone	DMFXUT8	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Oxymetholone.	Aplastic anaemia [3A70]	[12]
Troleandomycin	DMUZNIG	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Troleandomycin.	Bacterial infection [1A00-1C4Z]	[12]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[13]
LY2835219	DM93VBZ	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and LY2835219.	Breast cancer [2C60-2C6Y]	[12]
Pralatrexate	DMAO80I	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Pralatrexate.	Breast cancer [2C60-2C6Y]	[12]
Tucatinib	DMBESUA	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Tucatinib.	Breast cancer [2C60-2C6Y]	[12]
Bosutinib	DMTI8YE	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Bosutinib.	Breast cancer [2C60-2C6Y]	[12]
Trastuzumab Emtansine	DMU1LXS	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[12]
Fenofibric acid	DMGO2MC	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[12]
Macitentan	DMP79A1	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Macitentan.	Cardiovascular disease [BA00-BE2Z]	[12]
Chenodiol	DMQ8JIK	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Chenodiol.	Cholelithiasis [DC11]	[12]
Regorafenib	DMHSY1I	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Regorafenib.	Colorectal cancer [2B91]	[12]
Intedanib	DMSTA36	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Intedanib.	Colorectal cancer [2B91]	[12]
Pasireotide	DMHM7JS	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Pasireotide.	Cushing syndrome [5A70]	[12]
Ivacaftor	DMZC1HS	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Ivacaftor.	Cystic fibrosis [CA25]	[12]
Polatuzumab vedotin	DMF6Y0L	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Polatuzumab vedotin.	Diffuse large B-cell lymphoma [2A81]	[12]
Cannabidiol	DM0659E	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Cannabidiol.	Epileptic encephalopathy [8A62]	[12]
177Lu-DOTATATE	DMT8GVU	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[12]
Brentuximab vedotin	DMWLC57	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[12]
Rilpivirine	DMJ0QOW	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Tolvaptan	DMIWFRL	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[12]
Givosiran	DM5PFIJ	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[12]
Crizotinib	DM4F29C	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Crizotinib.	Lung cancer [2C25]	[12]
Ceritinib	DMB920Z	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Ceritinib.	Lung cancer [2C25]	[12]
Lurbinectedin	DMEFRTZ	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Lurbinectedin.	Lung cancer [2C25]	[12]
Alectinib	DMP1I6Y	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Alectinib.	Lung cancer [2C25]	[12]
BIBW 2992	DMTKD7Q	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and BIBW 2992.	Lung cancer [2C25]	[12]
Capmatinib	DMYCXKL	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Capmatinib.	Lung cancer [2C25]	[12]
Selpercatinib	DMZR15V	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Selpercatinib.	Lung cancer [2C25]	[12]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[12]
Calaspargase pegol	DMQZBXI	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[12]
Idelalisib	DM602WT	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Idelalisib.	Mature B-cell leukaemia [2A82]	[12]
IPI-145	DMWA24P	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and IPI-145.	Mature B-cell leukaemia [2A82]	[12]
Blinatumomab	DMGECIJ	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Blinatumomab.	Mature B-cell lymphoma [2A85]	[12]
Ponatinib	DMYGJQO	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Ponatinib.	Mature B-cell lymphoma [2A85]	[12]
Arry-162	DM1P6FR	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Arry-162.	Melanoma [2C30]	[12]
Vemurafenib	DM62UG5	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Vemurafenib.	Melanoma [2C30]	[12]
Ipilimumab	DMJTIYK	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Ipilimumab.	Melanoma [2C30]	[12]
Carfilzomib	DM48K0X	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Carfilzomib.	Multiple myeloma [2A83]	[12]
Panobinostat	DM58WKG	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Panobinostat.	Multiple myeloma [2A83]	[12]
Elotuzumab	DMEYHG9	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Elotuzumab.	Multiple myeloma [2A83]	[12]
Tecfidera	DM2OVDT	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Tecfidera.	Multiple sclerosis [8A40]	[12]
Siponimod	DM2R86O	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Siponimod.	Multiple sclerosis [8A40]	[12]
Fingolimod	DM5JVAN	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Fingolimod.	Multiple sclerosis [8A40]	[12]
Ozanimod	DMT6AM2	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Ozanimod.	Multiple sclerosis [8A40]	[12]
Fedratinib	DM4ZBK6	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Fedratinib.	Myeloproliferative neoplasm [2A20]	[12]
Entrectinib	DMMPTLH	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Entrectinib.	Non-small cell lung cancer [2C25]	[12]
ABIRATERONE	DM8V75C	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and ABIRATERONE.	Prostate cancer [2C82]	[12]
Ambrisentan	DMD1QXW	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Ambrisentan.	Pulmonary hypertension [BB01]	[12]
Axitinib	DMGVH6N	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Axitinib.	Renal cell carcinoma [2C90]	[12]
Tocilizumab	DM7J6OR	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Tocilizumab.	Rheumatoid arthritis [FA20]	[12]
Sarilumab	DMOGNXY	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Sarilumab.	Rheumatoid arthritis [FA20]	[12]
Larotrectinib	DM26CQR	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Larotrectinib.	Solid tumour/cancer [2A00-2F9Z]	[12]
LEE011	DMMX75K	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[12]
Methyltestosterone	DMWLFGO	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Methyltestosterone.	Solid tumour/cancer [2A00-2F9Z]	[12]
Fostamatinib	DM6AUHV	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Fostamatinib.	Thrombocytopenia [3B64]	[12]
Eltrombopag	DMOGFIX	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Eltrombopag.	Thrombocytopenia [3B64]	[12]
Lenvatinib	DMB1IU4	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Lenvatinib.	Thyroid cancer [2D10]	[12]
Elagolix	DMB2C0E	Major	Increased risk of hepatotoxicity by the combination of Mipomersen and Elagolix.	Uterine fibroid [2E86]	[12]
-----------


⏷ Show the Full List of 64 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7364).
2	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
3	Apolipoprotein B antisense inhibition--update on mipomersen. Curr Pharm Des. 2013;19(17):3132-42.
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
7	Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146.
8	US patent application no. 7,407,943, Antisense modulation of apolipoprotein B expression.
9	Canadian Pharmacists Association.
10	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
11	Cerner Multum, Inc. "Australian Product Information.".
12	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
13	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.